Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201609-01 Development of a new preclinical candidate targeting Histamnine-releasing factor to treat atopic dermatitis(Immunology, Protein) [01.31.2017]

PRINT

Development and Market Objectives

Our goal is to develop the leading compound for atopic dermatitis by evaluating the efficacy, PD/PK profile and in vitro stability of dTBP2 7mer peptide which inhibits histamine releasing factor (HRF), a new therapeutic target.

Unmet Medical Need & Target Patients

Currently, steroid drugs are mainly used for treating atopic dermatitis. However, due to serious side effects, it cannot be used for a long period of time, and it also acts as a symptom reliever, not a fundamental treatment. Therefore, the development of a fundamental treatment for atopic dermatitis is highly demanded. Most of the ongoing studies are targeting at the lower stages of the allergic signaling pathway, so it is difficult to expect good efficacy. It is therefore necessary to develop drugs that control the causative agent at higher levels, such as HRF.

Status

HRF targets were identified in atopic dermatitis animal models and in vivo preliminary efficacy and toxicity studies were completed. We are currently conducting studies to optimize the capacity of dTBP2.

Intellectual Property

[Deletion forms of IgE-dependent histamine releasing factor having histamine releasing activity, HRF-binding peptides and the uses thereof] - Patent registered in Korea (2007), Japan (2010), US (2010), EP (2016)

[Binding inhibitors of dimeric TCTP, IgE-dependent histamine release factor, and their receptors and the uses thereof] – Patent pending in PCT (2015), Korea, Japan, US, and EP (2016)

Competitive Advantages

Atopic dermatitis often recurs because it is difficult to know the etiology and treats to relieve symptoms. In this study, we intend to develop a first-in-class drug that essentially treats atopic dermatitis by blocking HRF. The major compound to be developed in this project, dTBP2, differentiates itself from other competitive drugs in that it blocks the upper levels of the allergic response by modulating HRF.     

Indication

Atopic dermatitis

Research Period

Jan. 16, 2017 ~ Apr. 15, 2018

Company

College of Pharmacy Ewha Womans University

Developmental Stage

Generation

Additional Information

Contact Information

Contact
Address Company Name: College of Pharmacy Ewha Womans University
WebSite Homepage: http://home.ewha.ac.kr/~pharm21/ Contact Person: Dr. Jeehye Maeng
E-mail: mengjeehye@hanmail.net Contact: +82-2-3277-3018

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code